Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Biomed Res Int. 2018 Nov 14;2018:4039173. doi: 10.1155/2018/4039173. eCollection 2018.
Yes-associated protein 1 (YAP1) is an effector of Hippo pathway, which plays a significant role in cell proliferation and tumor progression. The relationship between YAP1 and gastrointestinal cancer has been explored in many previous studies. We conducted a meta-analysis to explore the prognostic effect of YAP1 in patients with gastrointestinal cancer.
A systematic search was performed through the PubMed, Web of Science, Embase, and Cochrane library databases to collect eligible studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to evaluate the relationship between YAP1 expression and gastrointestinal cancer clinical outcomes.
A total of 2941 patients from 18 studies were enrolled. The results showed that elevated YAP1 expression predicted a poor prognosis in gastrointestinal cancer (HR = 1.56; 95% CI: 1.29-1.89; < 0.001). Subgroup analyses indicated significant association between YAP1 overexpression and shorter OS of patients with esophageal squamous cell carcinoma (HR = 1.85; 95% CI: 1.25-2.73; = 0.002), gastric cancer (HR = 1.41,95% CI: 1.02-1.95; = 0.037), and colorectal cancer (pooled HR = 1.75; 95% CI: 1.42-2.15; < 0.001). However, YAP1 expression did not affect DFS of patients with gastrointestinal cancer (pooled HR = 1.33; 95% CI: 0.95-1.88; = 0.101).
Elevated YAP1 expression in patients with gastrointestinal cancer might be related to shorter OS. YAP1 protein could serve as a potential predictor of poor prognosis in gastrointestinal cancer.
Yes 相关蛋白 1（YAP1）是 Hippo 通路的效应物，在细胞增殖和肿瘤进展中发挥重要作用。之前的许多研究已经探讨了 YAP1 与胃肠道癌之间的关系。我们进行了一项荟萃分析，以探讨 YAP1 在胃肠道癌患者中的预后作用。
通过 PubMed、Web of Science、Embase 和 Cochrane 图书馆数据库进行系统检索，收集符合条件的研究。使用合并的风险比（HRs）及其 95%置信区间（CIs）来评估 YAP1 表达与胃肠道癌临床结局之间的关系。
共有来自 18 项研究的 2941 名患者被纳入。结果表明，YAP1 表达升高预示着胃肠道癌预后不良（HR=1.56；95%CI：1.29-1.89；<0.001）。亚组分析表明，YAP1 过表达与食管鳞状细胞癌（HR=1.85；95%CI：1.25-2.73；=0.002）、胃癌（HR=1.41，95%CI：1.02-1.95；=0.037）和结直肠癌（合并 HR=1.75；95%CI：1.42-2.15；<0.001）患者的 OS 更短显著相关。然而，YAP1 表达并未影响胃肠道癌患者的 DFS（合并 HR=1.33；95%CI：0.95-1.88；=0.101）。
胃肠道癌患者 YAP1 表达升高可能与 OS 更短有关。YAP1 蛋白可作为胃肠道癌不良预后的潜在预测因子。
